Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cencora (COR)

Cencora raises fiscal 2026 adjusted EPS outlook; quarterly GAAP EPS $8.40

Positive Impact 4 of 5 guidance Written later

Cencora reported fiscal second-quarter results for the period ended March 31, 2026, with revenue up 3.8% year over year to $78.4 billion and adjusted diluted EPS up 7.5% to $4.75. GAAP diluted EPS of $8.40 was boosted by a $1.1 billion remeasurement gain tied to its OneOncology acquisition. The company raised its fiscal 2026 adjusted diluted EPS guidance to $17.65 to $17.90 and expects to repurchase $1 billion in shares by the end of calendar 2026.

Key points

  • Revenue of $78.4 billion, up 3.8% year over year; adjusted diluted EPS of $4.75 vs. $4.42 a year earlier
  • GAAP diluted EPS of $8.40 vs. $3.68 a year earlier, including a $1.1 billion gain on the OneOncology remeasurement
  • Fiscal 2026 adjusted diluted EPS guidance raised to $17.65 to $17.90 from $17.45 to $17.75
  • Cencora expects to repurchase $1 billion in shares by end of calendar 2026; quarterly dividend of $0.60 per share payable June 1, 2026

The filing

CompanyCencora (COR)
Form8-K, current report
Filed with the SECMay 6, 2026, 6:32 AM ET
Accession number0001140859-26-000018

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.